Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Non-Current Assets (2023 - 2026)

ArriVent BioPharma has reported Non-Current Assets over the past 4 years, most recently at $595000.0 for Q1 2026.

  • Quarterly results put Non-Current Assets at $595000.0 for Q1 2026, down 98.0% from a year ago — trailing twelve months through Mar 2026 was $25.6 million (down 67.37% YoY), and the annual figure for FY2025 was $272000.0, down 99.43%.
  • Non-Current Assets reached $595000.0 in Q1 2026 per AVBP's latest filing, up from $272000.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $48.0 million in Q4 2024 and bottomed at $272000.0 in Q4 2025.
  • Median Non-Current Assets over the past 4 years was $1.9 million (2023), compared with a mean of $10.7 million.
  • Peak annual rise in Non-Current Assets hit 8198.88% in 2025, while the deepest fall reached 99.43% in 2025.
  • Over 4 years, Non-Current Assets stood at $3.1 million in 2023, then skyrocketed by 1432.36% to $48.0 million in 2024, then crashed by 99.43% to $272000.0 in 2025, then surged by 118.75% to $595000.0 in 2026.
  • Business Quant data shows Non-Current Assets for AVBP at $595000.0 in Q1 2026, $272000.0 in Q4 2025, and $5.3 million in Q3 2025.